Aurinia Pharmaceuticals
AUPH
72 hedge funds and large institutions have $136M invested in Aurinia Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 8 closing their positions.
6% more call options, than puts
Call options by funds: $8.66M | Put options by funds: $8.18M
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
1% less funds holding
Funds holding: 73 → 72 (-1)
4.29% less ownership
Funds ownership: 32.04% → 27.74% (-4.3%)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
30% less capital invested
Capital invested by funds: $193M → $136M (-$57.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$5.04M |
| 2 |
Goldman Sachs
New York
|
+$3.14M |
| 3 |
Millennium Management
New York
|
+$3.07M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.61M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$909K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$12.6M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$10.1M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.18M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$852K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Walleye Trading
New York
| – | -$57K | -9,425 | Closed |
|
77
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$43K | -6,730 | Closed |
|
78
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$13K | -1,950 | Closed |
|
79
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$10K | -1,621 | Closed |
|
|
GCM
80
Gables Capital Management
Miami,
Florida
| – | -$6K | -850 | Closed |
|
AUPH Hedge Fund Activity: Q3 2019 in Review
72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2019, worth a combined $136M — down 30% from $193M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AUPH and 7 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 19 added.
The largest buyer was HealthCor Management, opening a new position worth an estimated $5.04M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.
- 72 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2019, down from 73 in Q2 2019.
- Funds reported $136M of Aurinia Pharmaceuticals stock for Q3 2019, down 30% quarter-over-quarter.
- 7 funds opened new Aurinia Pharmaceuticals positions in Q3 2019 and 8 closed out, a net change of -1 holder.
- The largest Aurinia Pharmaceuticals buyer in Q3 2019 was HealthCor Management, an estimated $5.04M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2019 was Fidelity Investments, an estimated $13.2M sold.
Based on aggregated 13F filings for Q3 2019.